{"id":"alendronate-and-zoledronate","safety":{"commonSideEffects":[{"rate":null,"effect":"Osteonecrosis of the jaw"},{"rate":null,"effect":"Atypical femoral fractures"},{"rate":null,"effect":"Esophageal irritation / ulceration"},{"rate":null,"effect":"Musculoskeletal pain"},{"rate":null,"effect":"Hypocalcemia"},{"rate":null,"effect":"Acute phase reaction (fever, myalgia, arthralgia)"}]},"_chembl":{"chemblId":"CHEMBL675","moleculeType":"Small molecule","molecularWeight":"271.08"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Alendronate and zoledronate are nitrogen-containing bisphosphonates that accumulate in bone and inhibit farnesyl pyrophosphate synthase in the mevalonate pathway of osteoclasts, leading to osteoclast apoptosis and reduced bone turnover. This mechanism decreases bone resorption and increases bone mineral density, making them effective for treating osteoporosis and other bone loss conditions.","oneSentence":"Bisphosphonates that inhibit osteoclast-mediated bone resorption by binding to hydroxyapatite on bone surfaces and reducing osteoclast activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:20:48.540Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women"},{"name":"Osteoporosis in men"},{"name":"Glucocorticoid-induced osteoporosis"},{"name":"Paget's disease of bone"},{"name":"Hypercalcemia of malignancy"}]},"trialDetails":[{"nctId":"NCT05091099","phase":"PHASE4","title":"The Optimal Sequential Therapy After Long Term Denosumab Treatment","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2022-01-10","conditions":"Osteoporosis","enrollment":44},{"nctId":"NCT05575167","phase":"","title":"Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)","status":"RECRUITING","sponsor":"424 General Military Hospital","startDate":"2023-11-28","conditions":"Osteoporosis, Postmenopausal","enrollment":125},{"nctId":"NCT04177940","phase":"PHASE4","title":"Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2020-08-17","conditions":"Osteoporosis","enrollment":45},{"nctId":"NCT02520362","phase":"","title":"Denosumab Safety Assessment in Multiple Observational Databases","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-05-31","conditions":"Osteoporosis","enrollment":517991},{"nctId":"NCT00580047","phase":"NA","title":"Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2003-12-01","conditions":"Renal Insufficiency","enrollment":59},{"nctId":"NCT05366621","phase":"","title":"Post-fracture Medication and Mortality","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-11-01","conditions":"Osteoporosis, Osteoporosis Fracture, Drug Therapy","enrollment":216155},{"nctId":"NCT01875458","phase":"","title":"Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2012-04-13","conditions":"Osteoporosis, With or Without Treatment, Bisphosphonate Treatment, Atypical Femur Fracture","enrollment":314},{"nctId":"NCT00896532","phase":"PHASE2","title":"Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-06-03","conditions":"Low Bone Mineral Density, Postmenopausal Osteoporosis","enrollment":419},{"nctId":"NCT04719572","phase":"NA","title":"Intervention Study of Drugs in Patients Osteopenia and Osteoporosis","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-03","conditions":"Osteoporosis, Osteopenia, Osteoporosis","enrollment":180},{"nctId":"NCT02731040","phase":"","title":"Exome Sequencing for Atypical Femoral Fractures","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-04","conditions":"Atypical Femoral Fractures, Osteoporosis, Bisphosphonate Therapy","enrollment":38},{"nctId":"NCT00404820","phase":"PHASE3","title":"Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-10","conditions":"Osteoporosis","enrollment":604}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":324,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Alendronate and Zoledronate","genericName":"Alendronate and Zoledronate","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bisphosphonates that inhibit osteoclast-mediated bone resorption by binding to hydroxyapatite on bone surfaces and reducing osteoclast activity. Used for Osteoporosis in postmenopausal women, Osteoporosis in men, Glucocorticoid-induced osteoporosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}